FLASCO OncoPod
af Florida Society of Clinical Oncology
Seneste episode
Empowering the Next Generation of Oncology: SOFLOH & the Fellows and…
Empowering the Next Generation of Oncology: SOFLOH & the Fellows and…
Om denne podcast
The FLASCO OncoPod is a podcast series that brings you engaging interviews and conversations with oncology champions and thought leaders. Each episode explores important topics in cancer care, from the latest clinical advancements to FLASCO events and initiatives. Whether it’s discussing groundbreaking research, policy updates, or sharing personal stories from members, the OncoPod keeps oncology professionals informed and connected. It’s your go-to source for staying up-to-date on FLASCO’s efforts to support and strengthen the oncology community across Florida.
Episoder
De nyeste 20 af 37 episoder
- Empowering the Next Generation of Oncology: SOFLOH & the Fellows and Residents Training Program · 19 min. · Sæson 1 Episode 36Join FLASCO OncoPod for a special conversation with Dr. Jani and Dr. Rosas as they highlight the South Florida Fellows Hematology Oncology (SOFLOH) initiative and the upcoming…
- The Nuance in mTNBC | Part 3: Toxicity, Delivery, and the Rest of the Journey · 20 min. · Sæson 1 Episode 35Selecting an effective treatment is only the beginning of managing metastatic triple-negative breast cancer (mTNBC). In this episode of The Nuance in mTNBC, Dr. Edgardo Santos…
- The Nuance in mTNBC | Part 2: The Patient the Trial Did Not Enroll · 16 min. · Sæson 1 Episode 34How should clinicians approach metastatic triple-negative breast cancer (mTNBC) when a patient's treatment history does not align with the populations studied in clinical trials?…
- The Nuance in mTNBC | Part 1: Where the Answers Split · 16 min. · Sæson 1 Episode 33Treatment decisions in metastatic triple-negative breast cancer (mTNBC) are becoming increasingly complex as new therapeutic options reshape the first-line landscape. In this…
- Drew Piers on Advocacy, Storytelling & Shaping the Future of Cancer Care · 23 min. · Sæson 1 Episode 32In this episode of the FLASCO OncoPod, Drew Piers, President of Sachs Media, explores the powerful role advocacy, storytelling, and strategic communications play in advancing…
- The Evolving Management of Hepatocellular Carcinoma: Prevention, Multidisciplinary Care, and Emerging Therapies · 29 min.Hepatocellular carcinoma (HCC) continues to present unique challenges for oncology teams, requiring coordinated multidisciplinary care and an evolving understanding of both liver…
- The Evolving Role of Community Oncology: Delivering Academic-Level Cancer Care Close to Home · 22 min. · Sæson 1 Episode 31In this episode of the FLASCO OncoPod, Dr. McDonough moderates a discussion with Dr. Wenk, Dr. Glick, and Dr. Patel, of Florida Cancer Specialists & Research Institute on the…
- Part 4, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types · 20 min. · Sæson 1 Episode 30In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the…
- Part 3, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types · 15 min. · Sæson 1 Episode 29In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the…
- Part 2, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types · 16 min. · Sæson 1 Episode 28In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the…
- Part 1, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types · 19 min. · Sæson 1 Episode 27In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the…
- CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors · 28 min. · Sæson 1 Episode 26The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians…
- What's New in Endometrial Cancer: Key Takeaways From SGO 2026 · 18 min. · Sæson 1 Episode 25Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of…
- ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia · 14 min. · Sæson 1 Episode 24What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care? In this episode of the FLASCO OncoPod, Dr. Robin Zon…
- "How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls · 8 min. · Sæson 1 Episode 23In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology…
- "How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions · 11 min. · Sæson 1 Episode 22In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients…
- "How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 1: When to Suspect aHUS in Oncology Patients · 7 min. · Sæson 1 Episode 21Atypical hemolytic uremic syndrome (aHUS) in patients with malignancy or undergoing cancer-directed therapy is likely under-recognized, yet early identification can have a…
- Advancing Care in GI and Biliary Tract Cancers Series Episode 4: GEA Disease State and Patient Management; Importance of the MDT · 18 min. · Sæson 1 Episode 20Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf, MD, of Tampa General Hospital Cancer…
- Advancing Care in GI and Biliary Tract Cancers Series Episode 3: HER2 Agents in GI Cancers - Understanding Mechanisms of Action · 20 min. · Sæson 1 Episode 19Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf of Tampa General Hospital Cancer Institute…
- Advancing Care in GI and Biliary Tract Cancers Series Episode 2: HER2 Testing in BTC and GEA · 22 min. · Sæson 1 Episode 18Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Paresh Patel and Dr. Masoumeh Ghayouri for the second…
